Uncategorized
Dr. Lukas Scheibler, Acucela’s EVP of R&D, Presents Optogenetics at Cell & Gene Meeting on the Mesa
SEATTLE--(BUSINESS WIRE)--Acucela Inc. (“Acucela”), a clinical-stage ophthalmology company and wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo 4596) committed to translating innovation into a diverse portfolio of drugs and devices to preserve and restore vision for millions of people worldwide, announced today that Dr. Lukas Scheibler, Executive Vice President of Research & Development, presented on human rhodopsin based optogenetics technology as a treatment cand